July 24, 2026
A New Jersey federal judge has thrown out for good a proposed nationwide class action alleging Zoetis Inc. hid the dangerous side effects of its canine osteoarthritis drug, finding the complaint failed to plead the plaintiffs relied on any misrepresentations to their dogs' detriment.
October 17, 2025
A New Jersey federal judge trimmed claims in a proposed class action accusing animal-health giant Zoetis Inc. of concealing safety risks tied to its canine arthritis drug Librela, finding that the pet owners failed to allege specific misrepresentations or viable product-defect theories.
October 10, 2024
New Jersey-based animal medication company Zoetis Inc. was hit with a proposed class action Wednesday alleging that a drug used to treat osteoarthritis in dogs has harmful effects such as seizures, inability to walk, organ damage and even death, which the company has failed to warn about.